Person:
GÜLÇEBİ İDRİZ OĞLU, MEDİNE

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

GÜLÇEBİ İDRİZ OĞLU

First Name

MEDİNE

Name

Filters

2019 - 201912020 - 20231
Reset filters

Settings

Has files: true × Subject: Life Sciences ×

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    PublicationOpen Access
    Taking action on climate change: testimonials and position statement from the international league against epilepsy climate change commission
    (2023-03-01) GÜLÇEBİ İDRİZ OĞLU, MEDİNE; Aledo-Serrano A., Battaglia G., Blenkinsop S., Delanty N., Elbendary H. M., Eyal S., Guekht A., Gulcebi M., Henshall D. C., Hildebrand M. S., et al.
    The release of the 2021 Intergovernmental Panel on Climate Change (IPCC) report makes clear that human activities have resulted in significant alterations in global climate. There is no doubt that climate change is upon us; chronic global warming has been punctuated by more frequent extreme weather events. Humanity will have to mitigate climate change and adapt to these changing conditions or face dire consequences. One under-appreciated aspect of this global crisis is its impact on healthcare, particularly people with epilepsy and temperature-sensitive seizures. As members of the inaugural International League Against Epilepsy (ILAE) Climate Change Commission, we recount the personal motivations that have led each team member to decide to take action, in the hope that our journeys as ordinary clinicians and scientists will help persuade others that they too can act to foster change within their spheres of influence.
  • Thumbnail Image
    PublicationOpen Access
    The effect of prenatal and postnatal caffeine exposure on pentylentetrazole induced seizures in the non-epileptic and epileptic offsprings
    (2019-11-01) GÜLÇEBİ İDRİZ OĞLU, MEDİNE; ONAT, FİLİZ; YAVUZ M., Albayrak N., Ozgur M., Oglu M., Cavdar S., Onat F.
    Caffeine, a central nervous system stimulant, has been reported to modulate seizure activity in various studies. In this study the effects of caffeine exposure on the pentylenetetrazole (PTZ) induced seizure thresholds and seizure stages in the Wistar and genetic absence epilepsy model offsprings were examined. Adult female and male Wistar rats and genetic absence epilepsy rats from Strasbourg (GAERS) consumed caffeine dissolved in water (0.3 g/L) before conception, during the gestational periods and lactation period whereas control groups of each strain received tap water. All offsprings at postnatal day 30 (PN30) subjected to 70 mg/kg of PTZ were evaluated in terms of overall seizure stages, the latency to the first generalized seizure and the c-Fos protein activity in the brain regions of somatosensorial cortex (SSCx), reticular thalamic nucleus (Rt), ventrobasal thalamus (VB), centromedial nucleus (CM) and lateral geniculate nucleus (LGN). The Wistar caffeine group had significantly shorter latency to the first generalized seizure (1.53 +/- 0.49 min) comparing to the Wistar control offsprings (3.40 +/- 0.68 min). GAERS caffeine group (6.52 +/- 2.48 min) showed significantly longer latency comparing to Wistar caffeine group (1.53 +/- 0.49 min). Although statistically not significant, GAERS caffeine group showed a longer latency comparing to the GAERS control group (4.71 +/- 1.82 min). In all regions of SSCx, Rt, VB, CM and LGN, GAERS caffeine group had lower c-Fos protein expression comparing to the GAERS control group (p < 0.05). Wistar caffeine rats had lower expression of c-Fos protein comparing to the Wistar control group only in SSCx. In CM, GAERS rats expressed lower c-Fos protein comparing to the Wistar control (p < 0.05). In conclusion differential effects of caffeine in the seizure modulation may involve c-Fos protein activity-dependent protection mechanisms.